These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 10470210)
1. Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure. Haese A; Huland E; Graefen M; Huland H Anticancer Res; 1999; 19(4A):2641-4. PubMed ID: 10470210 [TBL] [Abstract][Full Text] [Related]
2. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870 [TBL] [Abstract][Full Text] [Related]
3. Use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomy. Pruthi RS; Haese A; Huland E; Stamey TA Urology; 1997 Mar; 49(3):404-10. PubMed ID: 9123706 [TBL] [Abstract][Full Text] [Related]
4. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
5. Estimation of total PSA with a supersensitive PSA-assay during neo-adjuvant-chemotherapy of prostate cancer before radical resection of prostate. Spitz J; Enzmann T; Müller W; Weidenfeld M; Köllermann M Anticancer Res; 1999; 19(4A):2637-40. PubMed ID: 10470209 [TBL] [Abstract][Full Text] [Related]
6. Biochemical relapse of prostate cancer. Evidence after radical surgery. Prott FJ; Spitz J; Michaelis M; Niles B; Barth S; Köllermann M; Kleinschmidt K Anticancer Res; 2003; 23(2A):979-81. PubMed ID: 12820334 [TBL] [Abstract][Full Text] [Related]
8. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734 [TBL] [Abstract][Full Text] [Related]
9. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Schild SE; Wong WW; Novicki DE; Ferrigni RG; Swanson SK Urology; 1996 Jun; 47(6):878-81. PubMed ID: 8677580 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy. Nakamura M; Hasumi H; Miyoshi Y; Sugiura S; Fujinami K; Yao M; Kubota Y; Uemura H Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609 [TBL] [Abstract][Full Text] [Related]
11. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735 [TBL] [Abstract][Full Text] [Related]
12. Efficiency of ultrasensitive prostate-specific antigen assay in diagnosing biochemical failure after radical prostatectomy. Shimizu F; Tanaka S; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M Jpn J Clin Oncol; 2007 Jun; 37(6):446-51. PubMed ID: 17656483 [TBL] [Abstract][Full Text] [Related]
13. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. Shen S; Lepor H; Yaffee R; Taneja SS J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268 [TBL] [Abstract][Full Text] [Related]
14. The periurethral glands do not significantly influence the serum prostate specific antigen concentration. Oesterling JE; Tekchandani AH; Martin SK; Bergstralh EJ; Reichstein E; Diamandis EP; Yemoto C; Stamey TA J Urol; 1996 May; 155(5):1658-60. PubMed ID: 8627847 [TBL] [Abstract][Full Text] [Related]
15. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Tombal B; Van Cangh PJ; Loric S; Gala JL Prostate; 2003 Aug; 56(3):163-70. PubMed ID: 12772185 [TBL] [Abstract][Full Text] [Related]
17. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068 [TBL] [Abstract][Full Text] [Related]
18. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence. Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456 [TBL] [Abstract][Full Text] [Related]
19. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males. Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291 [TBL] [Abstract][Full Text] [Related]
20. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. King CR; Presti JC; Brooks JD; Gill H; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]